Cancer NetworkOriginal article
<![CDATA[Cevostamab Shows Durable Responses in Relapsed/Refractory Multiple Myeloma]]>
Phase 1positiveCevostamabPositive
AI Analysis
Summary
Cevostamab demonstrated durable responses in a Phase 1 trial for relapsed/refractory multiple myeloma, validating FcRH5 as a therapeutic target in the disease.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Durable responses demonstrated in relapsed/refractory multiple myeloma; FcRH5 validated as a good target
Importance:5/10
Sentiment:
0.65
multiple myelomaphase 1 dataFcRH5 targetoncology
Related Companies
Read the original article
Published by Cancer Network on July 30, 2026 4:00 PM